CT-388
ZYNERGY
Roche · Phase 2 · Not yet recruiting · Enrollment 486
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Arm 1: Petrelintide + Enicepatide Dosing Regimen 1 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Arm 2: Petrelintide + Enicepatide Dosing Regimen 2 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Arm 3: Petrelintide + Enicepatide Dosing Regimen 3 | Obesity or overweight | n/r | n/r | n/r | n/r |
| Arm 4: Petrelintide-matching Placebo + Enicepatide | Obesity or overweight | n/r | n/r | n/r | n/r |
| Arm 5: Petrelintide + Enicepatide-matching Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |
| Arm 6: Petrelintide-matching Placebo + Enicepatide-matching Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |